SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amgen Inc. - AMGN

Pomerantz LLP is investigating claims on behalf of investors of Amgen Inc. ("Amgen" or the "Company") (NASDAQ: AMGN). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.

The investigation concerns whether Amgen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On April 27, 2022, Amgen disclosed in its first quarter 2022 earnings release that "[o]n April 18, 2022, Amgen received a notice of deficiency from the [Internal Revenue Service (‘IRS')] for the 2013-2015 period proposing adjustments primarily related to the allocation of profits between certain of the Company's entities in the United States and the U.S. territory of Puerto Rico" which "seeks to increase Amgen's U.S. taxable income for the 2013-2015 period by an amount that would result in additional federal tax of approximately $5.1 billion, plus interest." The Company also disclosed that the IRS "notice proposes penalties of approximately $2 billion." On this news, Amgen's stock price fell sharply during intraday trading on April 28, 2022.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com

CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com  
888-476-6529 ext. 7980


News Provided by GlobeNewswire via QuoteMedia

AMGN
The Conversation (0)
bctx stock

BriaCell Appoints Renowned Pharmaceutical Veteran Jane Gross, Ph.D. to its Board of Directors

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) ("BriaCell" or the "Company") a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, is pleased to welcome the appointment of Jane Gross, Ph.D. to its Board of Directors.

Dr. Jane Gross is a highly experienced biotech executive with over 30 years in leading research and development teams from discovery through preclinical evaluation and clinical development of therapeutics for the treatment of cancer and autoimmune and inflammatory diseases. Dr. Gross currently serves as an Independent Director for aTyr Pharmaceuticals (Nasdaq: LIFE), a biotechnology company developing novel therapeutics for respiratory diseases and multiple cancer indications.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Exceptional silver and cobalt assays from seaweed

Exceptional silver and cobalt assays from seaweed

BPH Global (BP8:AU) has announced Exceptional silver and cobalt assays from seaweed

Download the PDF here.

Cizzle Brands Expands its Western Canadian Footprint With All Calgary Co-op and Freson Bros. Stores Now Selling CWENCH Hydration

Cizzle Brands Expands its Western Canadian Footprint With All Calgary Co-op and Freson Bros. Stores Now Selling CWENCH Hydration

As the CWENCH Hydrationâ„¢ brand continues to gain popularity, Cizzle Brands is strategically adding new retailers in select North American markets. Calgary Co-op and Freson Bros. are both chains of supermarkets in Alberta, and are expected to play a key role in building out the presence of CWENCH Hydrationâ„¢ in Western Canada.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart Failure

Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart Failure

Data demonstrates improvement in cardiac function and reductions in cardiac hypertrophy, remodeling, inflammation, and cell death - key underlying mechanisms in heart failure

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announced today the publication of research in the Journal of the American College of Cardiology: Basic to Translational Science ("JACBTS"), titled "Cannabidiol Prevents Heart Failure Dysfunction and Remodeling Through Preservation of Mitochondrial Function and Calcium Handling" (www.jacc.orgdoiabs10.1016j.jacbts.2024.12.009). This research was conducted by scientists from Tecnológico de Monterrey who, together with researchers from the DeBakey Heart and Vascular Center in Houston, TX, are collaborating with Cardiol on the development of the Company's proprietary subcutaneous ("SubQ") formulation of cannabidiol, CRD-38, to treat heart failure with preserved ejection fraction. This common form of heart failure remains a leading cause of hospitalization worldwide and is associated with a five-year mortality that exceeds 75% in hospitalized patients.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Canco Petroleum Begins Carrying Cizzle Brands' CWENCH Hydration Beverage in All of its Gas Stations Across Canada

Canco Petroleum Begins Carrying Cizzle Brands' CWENCH Hydration Beverage in All of its Gas Stations Across Canada

With a strong presence in British Columbia and Alberta and locations in Saskatchewan, Manitoba, New Brunswick, as well as Ontario, the availability of CWENCH Hydrationâ„¢ at all Canco locations enhances the brand's footprint across Canada in the key category of convenience retail.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Canco Petroleum Begins Carrying Cizzle Brands' CWENCH Hydration Beverage in All of its Gas Stations Across Canada

Canco Petroleum Begins Carrying Cizzle Brands' CWENCH Hydration Beverage in All of its Gas Stations Across Canada

With a strong presence in British Columbia and Alberta and locations in Saskatchewan, Manitoba, New Brunswick, as well as Ontario, the availability of CWENCH Hydrationâ„¢ at all Canco locations enhances the brand's footprint across Canada in the key category of convenience retail.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Canco Petroleum Begins Carrying Cizzle Brands' CWENCH Hydration Beverage in All of its Gas Stations Across Canada

Canco Petroleum Begins Carrying Cizzle Brands' CWENCH Hydration Beverage in All of its Gas Stations Across Canada

With a strong presence in British Columbia and Alberta and locations in Saskatchewan, Manitoba, New Brunswick, as well as Ontario, the availability of CWENCH Hydrationâ„¢ at all Canco locations enhances the brand's footprint across Canada in the key category of convenience retail.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×